Sanofi’s Amlitelimab Study: A Long-term Look at Atopic Dermatitis Treatment

Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

Sanofi is conducting a long-term extension study titled ‘A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.’ The study aims to assess the safety and efficacy of amlitelimab in individuals with moderate to severe atopic dermatitis who have participated in prior amlitelimab trials. This research is significant as it could provide insights into the long-term benefits and risks of amlitelimab, potentially influencing treatment protocols for atopic dermatitis.

The intervention being tested is amlitelimab, administered via subcutaneous injection. It is designed to treat moderate to severe atopic dermatitis, with additional treatments including topical corticosteroids, topical calcineurin inhibitors, and oral corticosteroids.

This interventional study follows a single-group assignment model without masking, focusing primarily on treatment. Participants will receive regular evaluations every four weeks, with some undergoing drug withdrawal to assess the durability of treatment response.

The study began on August 22, 2022, with an estimated completion date of June 25, 2025. These dates are crucial as they guide investors on the timeline for potential results and subsequent market actions.

The study’s progress could impact Sanofi’s stock performance by providing new data on amlitelimab’s effectiveness, potentially boosting investor confidence. As the pharmaceutical industry is highly competitive, advancements in treatment options for atopic dermatitis could position Sanofi favorably against competitors.

The study is ongoing, and further details are available on the ClinicalTrials portal.